Form 4: United Therapeutics CEO Executes Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the shares were sold in multiple transactions on April 21, 2026, at weighted average prices ranging from $564.35 to $575.72.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The reporting person retains direct ownership of 40,513 shares following these transactions, in addition to significant indirect holdings through family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it involves significant selling, the use of a pre-arranged 10b5-1 plan removes the signal of opportunistic insider trading.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.
• The CEO maintains a substantial remaining equity stake in the company, signaling continued alignment with shareholder interests.

Negatives

• The sale represents a liquidation of equity by the company's top executive, which can sometimes be perceived as a lack of confidence in future price appreciation, though this is mitigated by the pre-arranged nature of the plan.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, indicating ongoing future selling pressure from the CEO.

Future Outlook

The CEO's 10b5-1 plan remains active, with potential for further option exercises and sales of up to 1,734,410 shares through December 31, 2026.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive selling via 10b5-1 plans is a common practice in the biotechnology sector, allowing leadership to diversify personal holdings while maintaining transparency and regulatory compliance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for C-suite executives at large-cap biotech firms like Amgen or Gilead to manage equity compensation.
• The volume of shares sold relative to the CEO's total holdings is consistent with typical executive diversification strategies.

Related Party Transactions

• The filing discloses various holdings in family trusts where the reporting person or immediate family members are beneficiaries or trustees.

Stakeholder Impact

• Shareholders should be aware of the ongoing, scheduled selling program by the CEO, which may influence short-term liquidity.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Martine Rothblatt, Stock Options, 10b5-1 Plan